An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

Fortunato Morabito, Anna Grazia Recchia, Ernesto Vigna, Cirino Botta, Mamdouh Skafi, Mohammed Abu-Rayyan, Moien Atrash, Sara Galimberti, Lucio Morabito, Hamdi Al-Janazreh, Massimo Martino, Giovanna Cutrona, Massimo Gentile

Research output: Contribution to journalArticle

Abstract

Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Mantle-Cell Lymphoma
Appointments and Schedules
Therapeutics
Expert Testimony
Atrial Fibrillation
Publications
acalabrutinib
Stem Cells
Clinical Trials
Transplants
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Acalabrutinib
  • BTK
  • MCL
  • therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Morabito, F., Recchia, A. G., Vigna, E., Botta, C., Skafi, M., Abu-Rayyan, M., ... Gentile, M. (Accepted/In press). An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1689959

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. / Morabito, Fortunato; Recchia, Anna Grazia; Vigna, Ernesto; Botta, Cirino; Skafi, Mamdouh; Abu-Rayyan, Mohammed; Atrash, Moien; Galimberti, Sara; Morabito, Lucio; Al-Janazreh, Hamdi; Martino, Massimo; Cutrona, Giovanna; Gentile, Massimo.

In: Expert Opinion on Pharmacotherapy, 01.01.2019.

Research output: Contribution to journalArticle

Morabito, F, Recchia, AG, Vigna, E, Botta, C, Skafi, M, Abu-Rayyan, M, Atrash, M, Galimberti, S, Morabito, L, Al-Janazreh, H, Martino, M, Cutrona, G & Gentile, M 2019, 'An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma', Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1689959
Morabito, Fortunato ; Recchia, Anna Grazia ; Vigna, Ernesto ; Botta, Cirino ; Skafi, Mamdouh ; Abu-Rayyan, Mohammed ; Atrash, Moien ; Galimberti, Sara ; Morabito, Lucio ; Al-Janazreh, Hamdi ; Martino, Massimo ; Cutrona, Giovanna ; Gentile, Massimo. / An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. In: Expert Opinion on Pharmacotherapy. 2019.
@article{1c30a457149c49efaa294f1949fc9583,
title = "An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma",
abstract = "Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.",
keywords = "Acalabrutinib, BTK, MCL, therapy",
author = "Fortunato Morabito and Recchia, {Anna Grazia} and Ernesto Vigna and Cirino Botta and Mamdouh Skafi and Mohammed Abu-Rayyan and Moien Atrash and Sara Galimberti and Lucio Morabito and Hamdi Al-Janazreh and Massimo Martino and Giovanna Cutrona and Massimo Gentile",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14656566.2019.1689959",
language = "English",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

AU - Morabito, Fortunato

AU - Recchia, Anna Grazia

AU - Vigna, Ernesto

AU - Botta, Cirino

AU - Skafi, Mamdouh

AU - Abu-Rayyan, Mohammed

AU - Atrash, Moien

AU - Galimberti, Sara

AU - Morabito, Lucio

AU - Al-Janazreh, Hamdi

AU - Martino, Massimo

AU - Cutrona, Giovanna

AU - Gentile, Massimo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.

AB - Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms ‘mantle cell lymphoma’ and ‘acalabrutinib’. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are ‘fit’ and exhibit well-controlled disease, which often characterizes only a limited ‘niche’ among MCL patients.

KW - Acalabrutinib

KW - BTK

KW - MCL

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85075116099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075116099&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1689959

DO - 10.1080/14656566.2019.1689959

M3 - Article

AN - SCOPUS:85075116099

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

ER -